Journal of Cancer Biomoleculars and Therapeutics Officially Indexed in Embase

Journal of Cancer Biomoleculars and Therapeutics (JCBT, EISSN: 3060-8856) is pleased to announce that the journal has beenformally and actively indexed by Elsevier Embase, one of the most authoritative and influential biomedical databases worldwide.

As a core comprehensive biomedical database hosted by Elsevier, Embase strictly selects peer-reviewed academic journals with standardized publishing procedures, rigorous academic quality, and stable publication continuity. The active inclusion of JCBT fully recognizes the journal’s standardized editorial operation, reliable academic quality, and valuable academic contributions in the fields of cancer biomarkers, molecular oncology, and cancer therapeutics.

This Embase inclusion marks a new milestone in the journal’s international development. In the future, JCBT will continue to standardize editorial management, strictly control academic quality, focus on hot and frontier research directions in cancer biomedicine and therapeutics, and strive to provide a high-level international academic exchange platform for global researchers. The journal will keep expanding its global academic influence and promoting the innovative development and translational application of oncology research worldwide.

We sincerely thank all authors, reviewers, editorial board members, and readers for your long-term trust and support. We welcome more global scholars to submit high-quality manuscripts to JCBT and join us in promoting the progress of cancer biomolecular research and therapeutic innovation.

Editorial Office
Journal of Cancer Biomoleculars and Therapeutics
September 2026